Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | F13A1 | P00488 | 1/20 | 0.30 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | TGM1 | P22735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990062 | 1.00 | MET (0.34) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL19990061 | 1.00 | MET (0.34) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL16553194 | 0.93 | MET (0.33) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL29593959 | 0.93 | MET (0.33) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL15320316 | 0.93 | MET (0.33) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL16552835 | 0.92 | BCL2 (0.33) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL15320184 | 0.92 | MET (0.32) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL16552836 | 0.92 | BCL2 (0.33) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL15320102 | 0.92 | MET (0.32) | METBCL2BCL2L1MCL1MEN1 | |
| SCHEMBL16552670 | 0.92 | MET (0.32) | METBCL2BCL2L1MCL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300736-B1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2021-05-05 | — | — | EP | disclosed |
| EP-3277686-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2020-07-22 | — | — | EP | disclosed |
| US-10072006-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2018-09-11 | — | — | US | disclosed |
| WO-2018060484-A1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-04-05 | — | — | WO | disclosed |
| EP-3300736-A1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-04-04 | — | — | EP | disclosed |
| US-20180086761-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072006-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, PEPD, LCT | MET 4046/4885BCL2 463/4885BCL2L1 472/4885 |
| US-20180086761-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | NQO1, PEPD, BBOX1 | MET 3768/4885BCL2 463/4885BCL2L1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.